Onset: 30-60 minutes oral (tea or extract). Faster than valerian (which often takes 60-90 min).

Peak: 1-2 hours after dose.

Plateau: 2-4 hours of perceptible mild calm at typical 500 mg extract or 1-2 g dried herb tea.

Taper: 2-4 hour gradual fade. No "hangover," no residual cognitive impairment the next morning at typical doses.

Characteristic effects:

• "Background anxiety quieting" — most consistent descriptor. Not sedation, not euphoria — a gentle drop in baseline tension.
• Mild physical relaxation — slight reduction in muscle bracing, shoulder/jaw tension.
• Improved sleep onset at 500-700 mg taken 30-60 min pre-bed; rarely produces frank drowsiness.
• Cognitive performance preserved — Movafegh 2008 and Aslanargun 2012 both documented no psychomotor impairment.
• No euphoria, no high, no reinforcement. Users do not "want more" pharmacologically — this is a feature for safety, a limitation for hedonic users.

Honest variability: ~30-40% of users describe Passiflora as "subtle to imperceptible" at single doses; ~50% describe a clear but mild effect; ~10-15% find it noticeably calming. The variability tracks product quality, dose, and individual responsiveness (likely GABA-A subunit composition genetics) more than anything dramatic. Higher doses (700-1000 mg extract) raise the signal proportionally.

• No tolerance documented at standard doses across 4-week (Akhondzadeh) and 30-day (Harit 2024) trials.
• No withdrawal syndrome. Distinct from valerian (which can cause mild rebound insomnia on cessation after long heavy use) and dramatically distinct from benzodiazepines.
• Cycling not needed. Use continuously or PRN as preferred.
• Long-term use: the 2024 Carminati 12-month observational data supports Passiflora safety over 12 months at 200-600 mg/day.

Synergistic with

• L-theanine 100-200 mg: complementary anxiolytic mechanism (theanine = glutamate AMPA antagonism + alpha-wave EEG); pleasant pre-sleep pairing. Top community-stacked combination (76 dopamine.club mentions).
• Glycine 3 g (already V4-locked): sleep-onset support, separate mechanism (NMDA glycine site + glycinergic receptors in brainstem); clean additivity.
• Magnesium glycinate/threonate (already V4): GABAergic + NMDA modulation; clean additivity.
• Apigenin / chamomile / lemon balm: redundant target (all GABA-A flavonoid PAMs); rotate rather than stack to avoid diminishing returns.
• Ashwagandha (KSM-66, 300-600 mg): complementary mechanism (HPA-axis modulation); useful evening or daily combination for stress + sleep architecture.

Avoid stacking with

• Benzodiazepines (oxazepam, alprazolam, lorazepam, diazepam): theoretical CNS-depressant additivity; though Carminati 2024 used Passiflora to taper off benzos, the active period of co-use deserves clinical supervision.
• Z-drugs (zolpidem, eszopiclone, zaleplon): same caution.
• Barbiturates, gabapentinoids, GHB-class, phenibut: additive sedation; not lethal at Passiflora doses but unnecessary stacking.
• Alcohol: additive sedation; particularly in users naïve to passionflower (acute first-dose response can be slightly more sedating than expected).
• Opioids: theoretical respiratory depression additivity; clinically minor at Passiflora doses but worth noting.
• MAOIs (high-dose, non-selective — tranylcypromine, phenelzine): theoretical β-carboline contribution to MAO inhibition. At standardized Passiflora doses the β-carboline content is sub-pharmacological for MAO effects, but stacking with prescription MAOIs is unnecessary and theoretical risk.
• Strong sedating antihistamines (diphenhydramine, doxylamine): additive next-day grogginess.

Neutral / safe co-administration

• All of Dylan's V4 stack: theanine, glycine, magnesium, ashwagandha (KSM-66), creatine, fish oil, vitamin D3/K2, NAC, citicoline, alpha-GPC PRN, beta-alanine, curcumin, vitamin C. No documented interactions.
• Modafinil: mechanistically opposite (modafinil = wake; passionflower = calm). Timing-separated (modafinil AM, passionflower PM) is the obvious answer; same-day same-effect-tier use is fine.
• Selank (Dylan planning): no documented interaction; both anxiolytic but via different mechanisms (Selank = enkephalin-derived peptide neuropeptide modulation). Could be co-used in different contexts (Selank for acute social/competition anxiety; Passiflora for evening sleep wind-down).
• SSRIs / SNRIs: No documented interaction in Janda 2020 review. Avoid mega-doses; standard doses are clinically uncomplicated.
• Birth control, statins, antihypertensives, common antibiotics: no documented interactions.

Pharmacokinetics:

• No significant CYP induction/inhibition documented at standard doses. The β-carboline alkaloids could theoretically affect CYP1A2 if present at higher concentrations (some chemotypes contain more than others); standardized commercial extracts deposit too low for clinical CYP modulation.
• Excretion: primarily renal. No dose adjustment needed for normal hepatic/renal function.
• No detection on standard drug screens — Passiflora is not assayed in any clinical/employment urine drug screen panels.

Clinically significant pharmacodynamic interactions:

1. Sedative additivity — additive with benzodiazepines, Z-drugs, alcohol, opioids, barbiturates, gabapentinoids, sedating antihistamines, GHB-class. Magnitude is mild at typical doses but worth noting.

2. MAOI theoretical — high-dose Passiflora (> 1 g/day extract continuously) could theoretically push β-carboline-mediated MAO-A inhibition to a sub-clinical floor that adds to prescription MAOIs. Practical relevance: low for typical use, but avoid stacking with prescription MAOIs as a precaution.

3. Anticoagulants — coumarin content in some Passiflora preparations is low but documented; theoretical additive effect with warfarin. Not a typical issue at standard doses; mention to clinician if on warfarin.

4. Pregnancy contraindication — uterotonic; absolute contraindication. Lactation data limited; conservative recommendation is avoid.

5. Pre-surgical — most anesthesia teams recommend discontinuing 1-2 weeks before elective surgery despite Passiflora's specific use as pre-op anxiolytic in dedicated RCTs (Movafegh 2008, Aslanargun 2012). The conservative recommendation is to defer to anesthesiology; the trial data is reassuring at the single-dose pre-op level but doesn't address long-term sedative continuum.

6. No oral contraceptive interaction documented (relevant in case of comparison to St. John's Wort, which does).

No actionable PGx for Passiflora response as of 2026. This is mostly because the response is mild and the studied genetic substrates (GABA-A subunit polymorphisms — particularly GABRA2 and GABRG2) are more characterized for benzodiazepine and alcohol response than for flavonoid PAMs specifically.

GABA-A subunit variants (GABRA2, GABRG2, GABRA6, GABRB3): polymorphisms here predict benzodiazepine response and alcohol sensitivity; presumed but unconfirmed relevance to Passiflora flavonoid PAM response.

CYP1A2 polymorphism: Relevant only if Passiflora's β-carboline alkaloid content is high enough in a particular extract to engage CYP1A2 metabolism (most standardized extracts: not). CYP1A2 PMs would theoretically have higher β-carboline exposure on identical dose; clinical relevance: trivial at standard dosing.

HLA alleles — no reported associations with Passiflora hypersensitivity reactions.

Practical takeaway for Dylan (23andMe results expected June 2026): No Passiflora-specific PGx interpretation. Useful adjacent data: GABRA2 + GABRG2 variants (relevant for benzo/alcohol sensitivity generally) may give a soft hint about flavonoid PAM responsiveness, but treat as exploratory not prescriptive.

Sourcing-difficulty rating: easy. US OTC supplement market has standardized extracts available across price tiers. The friction is choosing a reputable brand with COA / third-party testing rather than the cheapest option.

For Dylan: Gaia Herbs liquid phyto-cap or Pure Encapsulations standardized extract. $25-35 for 60-90 day supply at 500 mg PRN evening dosing = effectively trivial cost.

Quality flags to look for:

• COA (Certificate of Analysis) available on request
• Standardization on label (3.5% isovitexin, 4% total flavonoids, or 2-4% vitexin)
• USP, NSF, or ConsumerLab verification preferred
• Single-herb formula (not buried in a "sleep blend")
• US- or EU-based manufacturer with traceable supply chain
• Heavy metal + PA testing if specifically called out (premium brands list this)

Baseline (before starting)

• Subjective anxiety VAS or GAD-7 score (1-week pre-use average)
• Subjective sleep quality VAS (1-week pre-use average); sleep-onset latency self-report
• HRV-night (Oura/Whoop/ring) baseline 7-day average — Dylan's Colmi R06 already in place via ring-health platform
• ALT/AST (covered in June 2026 baseline bloodwork panel) — for sourcing-quality reassurance, not because Passiflora is hepatotoxic
• Resting HR + BP (3-day morning average) — Passiflora typically null on cardiovascular metrics; baseline matters for comparison

During use

• Daily subjective anxiety + sleep quality VAS for first 2-3 weeks — primary endpoint is "do I notice anything." If null at 500 mg × 14 days, either escalate to 700-1000 mg trial × 7 days or discontinue (responder/non-responder split is real).
• Weekly HRV-night trend — looking for non-inferiority compared to baseline (no degradation) and ideally modest improvement on dose nights.
• Sleep-onset latency — subjective and Oura/ring measurement on dose nights vs non-dose nights (PRN dosing pattern enables clean A/B).
• Adverse effect surveillance — paradoxical agitation, jitteriness, headache, GI upset, drowsiness next morning. Discontinue if any consistent pattern.

Periodic (every 3-6 months)

• ALT/AST recheck if any liver concern develops (not expected at typical use); also if sourcing changes to a brand without COA.
• Reassess "is this providing value vs better-supported tools" — Passiflora has a low ceiling, so periodic recalibration prevents inertia.